P-142 Inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy with nab-paclitaxel and gemcitabine: A single-center study

A Ioannou,G Papaxoinis,P Gouveris,D Zouki,V Kardara,S Ioannou,K Exarchos,V Adamou,I Bitsas,G Karianakis,G Koronakis,N Stavrou,S Demiri

doi:10.1016/j.annonc.2022.04.232

P-142 Inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy with nab-paclitaxel and gemcitabine: A single-center study

A Ioannou, G Papaxoinis + Show 11 more

https://doi.org/10.1016/j.annonc.2022.04.232

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Jun 1, 2022

Affiliation: St Savas Hospital

#Inflammatory Biomarkers In Patients #Metastatic Pancreatic Ductal Adenocarcinoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The aim of the study was to examine the prognostic significance of inflammatory biomarkers in patients (pts) with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) undergoing first-line chemotherapy with nab-paclitaxel and gemcitabine (NPG).

Full Text